We surveyed U.S. neurologists in order to evaluate their knowledge of, and sources for, recent FDA safety warnings regarding antiepileptic drugs (AEDs) and whether they incorporate this information into their practices. Survey respondents (N = 505) were predominantly board-certified American Academy of Neurology members. Approximately 20% of respondent neurologists were not aware of warnings about four drug safety risks: suicidality with newer AEDs, increased birth defect risks from in utero divalproex exposure, impaired cognitive development from in utero divalproex exposure, and the requirement of haplotype screening in patients of Asian descent starting carbamazepine. Most respondents were aware of a recommendation for haplotype screening, yet did not routinely perform the safety screening, and 18 reported patients that had hypersensitivity reactions to carbamazepine. Respondents learned about drug safety risks from varied sources; only notifications from specialty organizations were associated with accurate knowledge of drug safety warnings. Most surveyed neurologists would prefer implementing "a formal warning process via specialty organizations" with e-mails of updated product insert warnings.
Introduction
Neurologists need up-to-date information on the safety of widely used medications to care for their patients effectively. The safety warnings of the FDA, however, are not systematically transmitted to neurologists who, as a result, may not become aware of major drug safety risks. The FDA reports these risks in "Drug Safety Communications" and "MedWatch Alert" e-mails, but these are only directly transmitted to neurologists registered for notifications. Physician specialty organizations, including the American Academy of Neurology (AAN), occasionally receive e-mail warnings of safety risks from the FDA, which may then be passed along to members. The FDA also requires that drug manufacturers update product inserts and highlight particularly severe or unusual drug safety risks in "black box" warnings and "Dear Health Care Provider" letters [1, 2] . Many neurologists learn of drug safety risks from published articles and continuing medical education (CME). It remains unclear, however, whether safety data are communicated to neurologists effectively and whether physicians implement recommended drug safety screening into their practices. Previous studies, for example, show that physicians are often aware of updated drug safety information but may not carry out recommended practices [3] [4] [5] .
Four new safety risks for antiepileptic drugs (AEDs) have been recently identified: increased suicidal thoughts or behavior with newer AEDs [6] , high risks for birth defects [7] and cognitive impairment [8] in the offspring of mothers receiving divalproex, and risks for hypersensitivity reactions in patients of Asian descent starting carbamazepine [9] . The empirical basis and causative relationships underlying some of the FDA warnings, particularly regarding suicidality, are controversial [10] . However, we believe it is important for neurologists to be aware of major drug safety warnings in order to incorporate appropriate safety screening procedures and patient counseling into their practices. We surveyed U.S. neurologists to determine whether they were aware of recent AED safety warnings, their sources of drug safety information, and whether they incorporate this safety information into their practices. This information may help identify optimal methods for imparting important safety updates to neurologists.
Methods

Standard protocol approvals and patient consents
This survey study meets the criteria for research exempt from IRB monitoring under Exemption 45 CFR 46.101(b) (2) . 
Survey
A master list of active members of the American Academy of Neurology (AAN) was stratified by state and systematically sampled. Surveys were transmitted to 4627 U.S. neurologists by three e-mail requests. The survey was conducted using "SurveyGizmo," an Internetbased survey tool. Neurologists were asked to answer questions without consulting outside sources.
Survey questions
Survey questions concerned the following four recently identified safety risks: (1) A high risk for hypersensitivity reactions (e.g., StevensJohnson syndrome and toxic epidermal necrolysis) with carbamazepine use has been associated with the HLA-B*1502 haplotype marker, which is more common in patients of Asian descent. The FDA recommends haplotype screening for patients of Asian descent before initiating carbamazepine therapy [11] . (2) The FDA identified a doubling of risk for "suicidality" in patients beginning treatment with 11 AEDs, with suicidal ideation risk increasing from 2.4 to 4.3 per 1000 patients. Though controversial among neurologists, the FDA recommends warning and monitoring patients who are prescribed these AEDs. (3) Recent studies have shown an increase in the previously reported risks for malformations in the offspring of women treated with divalproex, with a risk of approximately 10.7% at the time of the survey [7] . (4) A major longitudinal study recently identified increased risk for cognitive limitations in children after exposure in utero to divalproex, with a decrease of 6 to 9 IQ points compared to the offspring of mothers on one of three alternative AEDs during pregnancy [8] . Only preliminary findings are reported in the drug product insert [12] , and this was used as a test of knowledge of an evolving safety risk. We also included a control question; neurologists were asked whether they knew that lacosamide did not have "black box" safety warnings. Neurologists were also asked to rank five methods of distributing drug safety information from most effective to least effective. The complete list of survey questions and neurologist responses can be found in the supplementary addendum.
Statistical analysis
Respondents were scored on their knowledge of the exact level of risk cited by the FDA and on their knowledge of the existence of a significantly increased risk for the four new drug safety questions and the lacosamide control question. Knowledge of safety risks in neurologists who did and did not use each source was compared using a t-test. Additionally, chi-squared tests or ANOVA was used to test for dependence between demographics, practice characteristics, answers to individual questions, and use of each source of information.
Results
Characteristics of survey respondents
Six hundred five (13.1%) of the 4627 survey recipients completed and returned the survey within six weeks. One hundred respondents reported that they did not care for patients with epilepsy; responses from the remaining 505 were analyzed. Responses were received from all 50 states and the District of Columbia. The backgrounds of respondents were similar to national AAN membership: one-half (49.5%) were in solo or group practice, 66.5% were male, mean age was 48.9 years (range: 29-77), and survey respondents were in practice an average of 22.4 years (range: 3-52) [13] . The majority (54.0%) of survey respondents treat at least 100 patients with epilepsy each year. Compared to all AAN members, a slightly larger proportion of respondents had academic or government-based practices (27.1% AAN members; 39.8% survey respondents) and had board certification (76%; 96.4%) [13] (Table 1) .
Sources for drug safety information
Neurologists reported receiving drug safety information from multiple sources. The most common sources were the following: notifications from specialty organizations (67.1%), published literature (67.1%), colleague and/or peer (53.1%), and CME or other educational programs (52.9%) (Fig. 1 ). Respondent neurologists in academic and private clinical practices used many of the same sources of drug safety information. Private practice neurologists, however, were more likely to acquire their knowledge from pharmaceutical representatives (54.8% private, 23.4% academic), while academic neurologists were more likely to use published literature and colleagues/peers as sources (59.2% private, 75.1% academic). (Table 2) 3.3.1. FDA recommendation to perform haplotype screening prior to initiating carbamazepine therapy in patients with Asian heritage Seventy percent of respondents reported that they were aware of this 2007 FDA recommendation. While 147 neurologists (29.1%) reported initiating carbamazepine treatment in patients of Asian descent since the warning, only 33 of them (22.5%) said they performed haplotype screening. Eighteen neurologists reported that their patients of Asian descent had developed carbamazepine-related hypersensitivity reactions during this time period.
Drug safety survey responses
Suicidal ideation with newer AEDs
Of the respondents, 80.6% were aware of the FDA warning regarding suicidal thoughts; 70.1% reported counseling patients on this risk in the three years since the safety notification. Only 60.2% of respondents correctly identified the risk as 4.3 per 1000 (Fig. 2) . Many neurologists commented that the FDA's findings and recommendations are controversial and that knowing the exact risk of "suicidality" (itself a nebulous concept) is not essential to good clinical care.
Increased risks for birth defects with divalproex exposure
Only 33.5% of respondents were aware of the recently identified increased risk of birth defects in the offspring of mothers treated with divalproex. Many noted that it may be sufficient for them to be aware of an increased risk for birth defects but not of this specific risk. Nearly all (93.3%) respondents reported counseling women who were planning pregnancies on birth defect risks with divalproex ( Table 2) . Table 2 ). The remaining one-third of neurologists (30.7%) thought that "cognitive and development risks in offspring exposed to divalproex in utero has not been established." The current divalproex product insert does not include this specific risk but notes that "there have been reports of developmental delay, autism and/or autism spectrum disorder in the offspring of women exposed to valproate during pregnancy."
No "black box" warnings for lacosamide
Seventy-three percent of respondents correctly answered the control question and recognized that there was no "black box" warning for lacosamide (Table 2) .
U.S. neurologists' overall knowledge of drug safety warnings
Of the respondents, 73.9% knew of the increased risks associated with AEDs, as judged by their recognition of at least 4 of 5 safety issues queried. However, those who recognized specific levels of drug risks, such as rate of birth malformation with divalproex, were fewer: only 29.3% recognized specific drug risks for at least 4 of the 5 items queried, and only 6.7% knew all five.
Only one source of information, notifications from specialty organizations, was associated with increased specific knowledge and general recognition of drug safety risks (specific knowledge: t(333) = 2.53, p = 0.012; general recognition: t(321) = 3.33, p = 0.001).
Respondents' practice type, region of practice, years in practice, and age were not associated with their knowledge of drug safety issues. The number of patients with epilepsy treated each year was associated with a modest increase in knowledge of drug safety issues (specific knowledge: r s = 0.14, p = 0.002; general recognition: r s = 0.17, p b 0.001).
Neurologists' preferences for methods to receive updated drug safety information
Most neurologists prefer to receive safety information from structured, easily obtained sources. A large number endorsed the creation of "a formal warning process via specialty organizations" (n = 190) or e-mails with "updated product insert warnings to specialists in that field" (n = 176). Another 101 neurologists thought that pharmaceutical companies should be required to "notify physicians of all major safety updates on product inserts, not just the very serious 'black box' warnings." Few respondents (n = 24) prefer to "continue the current system unchanged," and even fewer (n = 14) prefer relying on safety information from FDA websites.
Discussion
The U.S. neurologists in the survey received drug safety warnings from multiple sources; however, safety information was not systematically delivered, and approximately one-fifth of survey respondents (17-27% across the five safety issues) were unaware of recently reported safety risks with AEDs. Neurologists who treated large numbers of patients with epilepsy had an increased knowledge of drug safety risks compared to other neurologists, though geographic distribution, years in practice, board certification, and age were not associated with increased knowledge. The only method of safety notification that was associated with an increased knowledge of drug risks was notifications from specialty organizations.
Many neurologists said that they disagreed with the significance of several of the FDA warnings. For example, many felt that the FDA's evidence for increased risk of suicidality with AEDs was flawed, did not include key risk factors for suicide such as depression, and should not necessarily be included in counseling. In a previous 2008 survey by Shneker et al. [14] , many neurologists thought that the FDA warning on suicidality risks with AEDs was unclear, and they were not counseling patients on this risk. Some respondents also felt that having a general awareness of drug safety risks was sufficient in making clinical decisions. Many, however, did not recognize the general levels of risk which would be necessary to assess even controversial safety warnings. For example, knowing that the FDA's reported risk for suicidality with new AEDs is relatively low (4.3 per 1000) is helpful in deciding whether to counsel patients on the risk. The FDA's recommended pharmacogenomic screening to avoid carbamazepine-associated hypersensitivity reactions did not appear to be effective-many survey neurologists had recently treated Asian patients with carbamazepine and yet, despite recognizing an association between the HLA-B*1502 haplotype and carbamazepine hypersensitivity reactions, failed to screen their patients for the haplotype; 18 neurologists reported Asian patients developing hypersensitivity reactions. This is consistent with previous studies showing that the majority of physicians eventually become aware of FDA drug safety advisories but that they often do not carry out the recommended safety screening procedures [4, 5, 15] . Physicians, for example, often continue prescribing contraindicated concurrent medications despite drug safety warnings [16] . Pharmacogenomic safety screening may have failed for multiple reasons, including the following: the FDA did not provide technical information on how to obtain and interpret haplotype testing, specialty organizations have not endorsed or encouraged testing, and logistical difficulties in obtaining testing while delaying treatment may be a barrier for neurologists. In addition, 30% of respondents were not aware of a requirement to perform haplotype screening.
The difficulty of incorporating new information into neurologists' practices is not exclusive to AED safety risks. For example, an AAN practice parameter recommending early epilepsy surgery screening for patients with medically resistant seizures did not reduce the 17-year average period of patients' pharmacotherapy before they were referred for surgery evaluation [17] . It is possible that, similar to AED suicidality warnings, neurologists disagreed with the practice recommendation. Our survey showed, though, that neurologists receive medical updates nonsystematically from varied sources, and it is likely that many neurologists were not aware of the practice recommendation.
Electronic medical record (EMR) technology would be ideal for personalizing safety warnings at point of care; for example, prescribers ordering carbamazepine for Asian patients could be warned that the patient needs haplotype screening. EpiCare (EPIC), a widely used electronic medical record tool, automatically warns prescribers of potentially dangerous drug interactions, but it does not link patient factors and drug safety warnings, e.g., when women of childbearing age are prescribed divalproex, it does not warn prescribers of high malformation risks.
We used an Internet survey to permit adaptive questions; however, the low yield of 13.1% could select for specific responses-for example, physicians more knowledgeable about safety risks (or perhaps less knowledgeable) might be more likely to respond. In a national survey on colorectal cancer, a much higher proportion of physicians preferred mail (90%) than Internet (6%) practice surveys, suggesting that neurologists might also be best surveyed via mailings [18] . Nonetheless, over 500 U.S. neurologists from all U.S. states and practice types responded, with relatively uniform patterns of responses. Moreover, the sample was typical for U.S. board-certified neurologists and AAN members: all practice types were represented, with the majority of neurologists in private practice; neurologists' years in practice ranged from 1 to 52 years. In addition, a sensitivity analysis showed consistent responses across respondents; practice type, location, and years in practice had little effect on knowledge of drug safety issues. Another limitation of the questionnaire was that multiple-choice questions were used, individual responses could not be explored, and only warnings for antiepileptic drugs were probed. Overall, survey respondent backgrounds were typical of board-certified U.S. neurologists, with the majority in private practices and a slightly higher proportion of academic neurologists responding than in the overall AAN membership.
Our findings raise several important issues on how drug safety screening could be better communicated and implemented. Many neurologists received new safety information from the FDA, published literature, and product insert updates; however, the sources of safety information varied considerably among neurologists, and neurologists noted that there was no systematic delivery of safety information. Despite using multiple sources, neurologists reported that drug safety information was most effectively transmitted via specialty organizations. These survey results suggest that it may be helpful for the FDA to review controversial safety warnings and to implement drug safety screening programs with advisory panels and specialty organizations. Neurologists would prefer that FDA safety warnings be communicated more systematically via e-mail summaries specific to their specialties. For pharmacogenomic screening, an FDA risk evaluation and mitigation screening (REMS) program could be implemented which requires safety screening before prescribed drugs are released by pharmacies, e.g., the vigabatrin vision safety SHARE program [19] . A risk mitigation program may, however, be difficult to implement for a small at-risk U.S. population and may be more appropriate for more frequent, serious drug risks.
Conclusion
Previous studies have identified the absence of a structured, systematic approach to disseminating important drug safety information to U.S. health-care providers [2, 3] . They have also shown that FDA drug safety communications are most effective when they are specific and repeated and when they provide alternative care options to providers [2] . Our survey showed that only notifications from specialty organizations improved neurologists' knowledge of drug safety risks. Neurologists in the survey strongly suggested that the current system of disseminating drug safety warnings be changed. Most frequently, they expressed a preference for a formal drug safety warning process directed by specialty organizations. Many would prefer electronic safety updates for drugs in their specialty field. Whether a revised drug safety notification system could be devised to improve knowledge among the approximately 20% of neurologists who do not recognize important safety risks despite reporting exposure to multiple sources for drug information remains to be determined.
